Weight loss · Wilmington, NC
Weight loss and obesity studies in Wilmington, NC
13 recruiting studies have a site in Wilmington.
13 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Wilmington, NC + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Wilmington, NC + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Novo Nordisk A/S
- Location
- Wilmington, NC + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Wilmington, NC + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Wilmington, NC + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Wilmington, NC + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Wilmington, NC + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
- Location
- Wilmington, NC + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S
- Location
- Wilmington, NC + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company
- Location
- Wilmington, NC + 55 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Novo Nordisk A/S
- Location
- Wilmington, NC + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Wilmington, NC + 12 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk A/S
- Location
- Wilmington, NC + 18 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.